Desmopressin and the risk of hyponatremia: A population-based cohort study.

ABSTRACT: BACKGROUND:Desmopressin was approved by the Food and Drug Administration (FDA) in 1978 for use in diabetes insipidus and bleeding disorders, but it is also prescribed off-label for patients with nocturia. Quantifying the potential risks facing adult patients taking desmopressin has taken on added importance because a new intranasal formulation of desmopressin was approved by the FDA in 2017. Like the old formulation, the main active ingredient is desmopressin acetate, but the new formulation also contains an excipient designed to enhance absorption. Our objective was to quantify the rate of hyponatremia in routine clinical care for patients prescribed the older formulation of desmopressin. METHODS AND FINDINGS:We conducted a population-based new-user cohort study from 1 February 2006 to 1

SUBMITTER: Fralick M 

PROVIDER: S-EPMC6802819 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature